**QUEEN'S
UNIVERSITY
BELFAST**

Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold

Krasavin, M., Lukin, A., Zhurilo, N., Kovalenko, A., Zahanich, I., Zozulya, S., Moore, D., & Tikhonova, I. G. (2016). Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold. *Bioorganic & Medicinal Chemistry*, 24(13), 2954–2963. <https://doi.org/10.1016/j.bmc.2016.04.065>

Published in:
Bioorganic & Medicinal Chemistry

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

© 2016 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>, which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold

Mikhail Krasavin,* Alexey Lukin, Nikolay Zhurilo, Alexey Kovalenko, Ihor Zahanich, Sergey Zozulya, Daniel Moore, and Irina G. Tikhonova

Novel free fatty acid receptor 1 (~~GPR40~~) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold

Mikhail Krasavin,^{a,*} Alexey Lukin,^b Nikolay Zhurilo,^b Alexey Kovalenko,^b Ihor Zahanich,^c Sergey Zozulya,^{c,d} Daniel Moore,^e and Irina G. Tikhonova^e

^a *Institutes of Chemistry and Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, 199034 Russian Federation*

^b *Lomonosov Institute of Fine Chemical Technologies, Moscow Technological University, 86 Vernadskogo Prospekt, Moscow, 117571 Russian Federation*

^c *Enamine Ltd, 78 Chervonotkatska, Kyiv 02094, Ukraine*

^d *Taras Shevchenko National University, 62 Volodymyrska, Kyiv 01033, Ukraine*

^e *Molecular Therapeutics, School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast BT9 7BL, Northern Ireland, UK*

* Corresponding author; phone: +7 931 3617872, fax: +7 812 428 6939.

E-mail address: m.krasavin@spbu.ru

ABSTRACT

Free fatty acid receptor 1 (FFA1), previously known as GPR40 is a G protein-coupled receptor and a new target for treatment of type 2 diabetes. Two series of FFA1/~~GPR40~~ agonists employing-utilizing a 1,2,4,1,3,4-thiadiazole-2-carboxamide scaffold ~~in their structure have been investigated~~ were synthesized. Both series offered significant improvement of the potency compared to the ~~earlier-previously~~ described 1,2,4,1,3,4-thiadiazole-based FFA1/~~GPR40~~ agonists and high selectivity for FFA1. ~~Structural-Molecular docking predicts new aromatic interactions with the receptor that improve agonist understanding of the basis for such an improvement potency has been gained.~~ The ~~lead compounds~~ most potent compounds from both series ~~have been~~ were profiled for ~~their~~ in vitro ADME properties (plasma and metabolic stability, LogD, plasma protein binding, hERG binding and, CYP inhibition). One series suffered very rapid degradation in plasma and in presence of mouse liver microsomes. However, the other series delivered a lead compound that displayed ~~an excellent~~ a reasonable ADME profile together with the improved FFA1 potency. ~~across the panel of tests on top of the improved FFA1/GPR40 agonist potency.~~

Keywords:

GPR40, free fatty acid receptor 1, FFA1, agonists, bioisosteric replacement, total polar surface area, cLogP, metabolic stability, aqueous solubility.

1. Introduction

Agonists of free fatty acid receptor 1 (FFA1, also known as GPR40 prior to its de-orphanization¹ in 2003) hold a particular promise ~~have the potential to become~~ an attractive alternative to the currently used anti-diabetic agents, most of which ~~lower glucose levels irrespective of the basal blood glucose concentration and can~~ cause hypoglycemia.¹ FFA1 is highly expressed in the insulin-expressing beta cells of the pancreas and increases insulin secretion in a glucose-dependent manner, thus reducing risk of causing hypoglycemia. ~~Under normal glycemia homeostasis, FFA1 expression (primarily, in pancreatic islets of Langerhans) is low and increases only in hyperglycemic state. At higher expression levels, activation of the receptor by small molecule agonists triggers a signaling cascade that raises the levels of insulin, lowers the glucose levels and, consequently, downregulates FFA1 itself.~~² Thus, the new therapeutic approach does not carry the danger of causing hypoglycemia (i. e. bringing the blood glucose concentration to dangerously low levels). Development of FFA1 agonists could provide therefore a new class of therapeutic agents. ~~This has led to an extensive research effort aimed at developing a new class of agents to treat type 2 diabetes mellitus (T2DM).~~³ However, the area of FFA1 agonist-based therapeutic targeting therapy was adversely affected by the late-2013 discontinuation of phase III trial of Takeda's first-in-class agent fasiglifam (TAK-875).⁴ ~~At the time of writing this manuscript, merely one clinical trial of an FFA1 agonist (Piramal's compound P11187 of the undisclosed structure) was conducted.~~⁵ The unexpected toxicity issues aside, the antidiabetic efficacy of TAK-875 was established in the course of Takeda's clinical ~~investigation of the drug trials, thereby providing the proof of principle for the entirely new therapeutic approach.~~⁶ At the time of writing this manuscript, merely one clinical trial of an FFA1 agonist (Piramal's compound P11187 of the undisclosed structure) has been conducted.⁵ ~~Therefore~~ It is expected that, the future quest for efficacious and safe FFA1 agonists should primarily focus on tackling their liver toxicity profile.⁷

The toxicity has been linked to the high lipophilicity of TAK-875 as well as most reported FFA1 agonists.⁷ An increase in the total polar surface area (TPSA, Å²) of FFA1 agonists could, in principle, provide a ~~straightforward~~ solution to the problem. However, TAK-875 and many other advanced compounds of this class (such as Amgen's AMG-837,⁸ and Eli Lilly's LY2881835³) are based on the 3-[4-(benzyloxy)phenyl]propanoic acid core, which mimics the fatty acid endogenous ligands of the receptor (Figure 1). Hence, imparting too much polarity to a FFA1 agonist may simply render the ligand inactive.

Commented [IT1]: This is not true.

Commented [IT2]: Cannot understand the meaning of this part of the sentence

Commented [IT3]: You don't use it afterwards.

Figure 1. Advanced GPR40 agonists containing the 3-[4-(benzyloxy)phenyl]propanoic acid core.

One effective approach to fine-tuning the lipophilicity profile of FFA1 agonists is to ‘decorate’ the 3-phenylpropanoic acid scaffold with polar heterocyclic moieties.⁹ Alternatively, this scaffold itself could be replaced with heterocyclic isosteres (as in Takeda’s compounds **1**¹⁰, **2**¹¹ and **3**¹² as well as Amgen’s indole-based compound **4**¹³ shown in Figure 2).

Recently, we [have](#) reported on the design and synthesis of a series of compounds containing the 3-(1,3,4-thiadiazol-2-yl)propionic acid moiety (cLogP = -0.09) in lieu of the 3-phenylpropanoic acid moiety (cLogP = 1.84).¹⁴ The best compound in the series (**5**) displayed moderate agonist potency against [GPR40-FFA1](#) (EC₅₀ = 5.93 μM) and an excellent *in vitro* ADMET profile (plasma protein binding, aqueous solubility and microsomal stability). The lower potency of **5** (compared, for example to TAK-875, [GPR40-EC](#)₅₀ = 0.014 μM¹⁵) can be rationalized by the overly polar character of the [4,2,4,1,3,4](#)-thiadiazole-2-carbozamide used in lieu of the (4-benzyloxy)phenyl moiety (*vide supra*). In this work, we investigated two compound series that stem from the initial series (represented by compound **5**): i. [4,2,4,1,3,4](#)-thiadiazole-2-carbozamides **6** designed to bring back the lipophilicity of the series (introduction of an additional phenyl ring results in a cLog P increase by two units¹⁶) and thus improve its potency; ii. 3-phenylpropanoic acids **7** containing the [4,2,4,1,3,4](#)-thiadiazole-2-carbozamide periphery, designed with the same ‘polar appendage’ approach in mind as explored by us earlier⁹ (Figure 3).

Figure 2. Structures of heterocyclic analogs of 3-phenylpropanoic acid-based GPR40 agonists **1-4**.

Figure 3 Two chemical series (**6** and **7**) explored in this work. [4,2,4,1,3,4](#)-thiadiazole-2-carbozamide is highlighted.

Both sets of potential GPR40 agonists (**6a-e** and **7a-l**) were tested for FFA1 activation using a calcium flux assay conducted on Chinese hamster ovary (CHO) cells. All compounds were tested in concentration-response (% GPR40 activation) mode in order to determine EC_{50} values, which are presented in Table 1.

Table 1. Structures, chemical yields, and GPR40 activation activities data and lipophilicities of agonists **6a-e** and **7a-l**.

Compound	R	Isolated yield (%)	GPR40 $EC_{50} \pm SD$, μM^*	cLogP ¹⁶
6a	3-(3-MeC ₆ H ₄)	82	0.76 ± 0.08	3.87 ± 0.64
6b	3-(3-ClC ₆ H ₄)	80	1.69 ± 0.12	3.98 ± 0.65
6c	3-(4-FC ₆ H ₄)	78	1.28 ± 0.15	3.35 ± 0.69
6d	3-(2-furyl)	64	1.64 ± 0.12	2.72 ± 0.65
6e	BnO	76	17.94 ± 3.28	3.08 ± 0.65
7a	H	60	1.06 ± 0.14	2.78 ± 0.64
7b	4-MeO	62	>10.00	2.73 ± 0.64
7c	2-F	58	0.58 ± 0.10	2.75 ± 0.64
7d	3-Me	54	1.77 ± 0.17	3.24 ± 0.64
7e	4-F	58	6.64 ± 1.87	3.23 ± 0.67

7f	2-Me	56	1.52 ± 0.18	3.24 ± 0.64
7g	4-Cl	63	3.69 ± 0.95	3.77 ± 0.64
7h	3-F	55	1.19 ± 0.19	3.27 ± 0.67
7i	3-MeO	62	4.68 ± 0.80	3.04 ± 0.64
7j	3,4-diF	70	0.58 ± 0.09	3.62 ± 0.70
7k	4-Me	54	4.30 ± 1.56	3.24 ± 0.64
7l	3-Cl	54	10.62 ± 1.02	3.81 ± 0.65

* Each value is an average of $n = 4$.

In analyzing the data on biological activity against FFA1, it should be borne in mind that the anilide periphery in the series of the receptor agonists represented by compound **5** was designed so as to impart higher lipophilicity to otherwise overly hydrophilic 3-(~~4,2,4~~~~1,3,4~~-thiadiazol-2-yl)propanoic acid scaffold (*vide supra*) and thus increase affinity to the receptor (the physiological activation of which is triggered by endogenous fatty acid ligands like eicosatienoic acid).¹⁸ From the data obtained for ~~a~~ even a small set (**6a-e**) of higher-logP analogs of compound **5**, it becomes apparent that our hypothesis of using lipophilicity as a driver of potency against FFA1 was correct. Indeed, four out of five analogs had significantly higher potency compared to **5**, ~~(with the best compound, 6a, leading into the sub-~~micromolar range). The lower potency of **6e** most is likely due to conformational rigidity requirement in the portion of the molecule opposite to carboxylic acid functionality, which is present in biphenyl analogs **6a-d** and is lost after introduction of the -CH₂O- linker in **6e**.

The overall very satisfactory potency profile of compounds **7a-l** suggests that ~~4,2,4~~~~1,3,4~~-thiadiazole-2-carboxamide moiety was a suitable periphery group to add to the 3-phenylpropanoic acid core in order to improve affinity to FFA1. The agonist activity in this series appears to be particularly sensitive to the substitutions in the anilide moiety, thus attesting for the importance of the latter for building efficient interactions with the receptor. Clearly, substitution in position 4 of the phenyl ring is particularly detrimental for the activity (**7b**, **7g**, **7e**, **7k**). Substituents in positions 2 and 3 seem to be well tolerated, with ~~one of two~~~~the~~ most active compounds (**7c**) having fluorine in position 2. The high potency of the 3,4-difluorophenyl compound (**7j**) is somewhat surprising in light of the relatively low potency of the 4-fluorophenyl compound (**7e**).

~~It was important to establish~~ We next evaluated the selectivity profile of the most potent GPR40 agonists from both series studied here (**6a**, **6c**, **7c** and **7j**) against other GPCRs binding free fatty acids/free fatty acid receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). ~~While the four FFARs share a significant similarity,~~ GPR41-FFA2 and GPR43-FFA3 agonists ~~are usually~~ have a preference in binding shorter-short-chain fatty acids while GPR40-FFA1 and GPR120-FFA4 have a higher affinity to medium-

Commented [IT4]: Don't understand why you need this addition.

Commented [IT5]: This is so obvious. I don't think this is a hypothesis.

Commented [IT6]: They don't really share significant similarity

and long-chain fatty acids.^{19,20} As it is seen from the ~~activation-activity~~ data against this panel of ~~GPRs~~GPCRs, the four lead compounds displayed high selectivity for GPR40-FFA1 (Table 2).

Table 2. Selectivity profile for compounds **6a**, **6c**, **7c** and **7j**.^a

???	6a	6c	7c	7j
human FFA1/GPR40 EC ₅₀ (μM)	0.76	1.28	0.58	0.58
human FFA3/GPR41 EC ₅₀ (μM)	>10	>10	>10	>10
human FFA2/GPR43 EC ₅₀ (μM)	>10	>10	>10	>10
human FFA4/GPR120 EC ₅₀ (μM)	>10	>10	>10	>10

^a Each values is an average of n = 4 in the presence of 0.1% BSA.

Figure 4. Docked poses of compounds **5** and **6a** at FFA1.*

* (A) Overlay of **5** and **6a** in the FFA1 binding site. Compounds **5** and **6a** are in ~~magenta~~cyan and ~~yellow~~magenta color, respectively. Protein-ligand interactions are visualized for compound **6a** only. (B) Hydrophobic interactions of the terminal ring of compound **5** with FFA1. (C) Hydrophobic and π-π interactions of the biphenyl moiety of compound **6a** with FFA1. Hydrogen bonds, π-π and hydrophobic interactions are in a brown, blue and yellow dashed-line, respectively. Residues are labeled with their position followed by the Ballesteros and Weinstein numbering.²¹ Transmembrane helices are labeled in red, Roman numerals.

To gain a structural understanding of improved potency of **6a** compared to **5**, we have docked **6a** and **5** in the FFA1 binding site. As visualized in Figure 4A, both compounds have a similar orientation within the binding cavity forming hydrogen bonds with R183_{5.39}, Tyr91_{3.37}, Tyr240_{6.51} and the backbone of L138_{4.57}. While the more potent agonists (TAK-875, AMG 837 and LY2881835) substitute the 1,3,4-thiadizole with a more hydrophobic benzene ring, thiadizole is still well accommodated within the binding site. This can be justified by its propensity to form π - π interactions with W174_{EL2} and possibly F87_{3.33}.

The phenyl ring of **5** is at the interhelical space of helices 3 and 4, forming hydrophobic interactions with V84_{3.30}, F88_{3.34} and F142_{4.61} (Figure 4B). In contrast, the same phenyl ring of **6a** positions deeper within the binding cavity forming π - π stacking interactions with F88_{3.34} and F142_{4.61} (Figure 4C). It appears that the addition of a second phenyl ring in **6a** slightly pulls the molecule inside the helical bundle. This is due to involvement of the second phenyl ring in hydrophobic interactions with V84_{3.30} and L135_{4.54} and the π - π stacking interaction with F88_{3.34}. The formation of the aromatic network with the receptor could explain the 10-fold increase in potency observed for **6a** compared to **5**.

Figure 5. Overlay of the docked pose of compound **7c** (orange) with the crystal structure conformation of TAK-875 (green) in the FFA1 binding site.*

* Protein-ligand interactions are visualized for compound **7c** only. Hydrogen bonds, π - π and hydrophobic interactions are in a brown, blue and yellow dashed-line, respectively. Residues are labeled with their position followed by the Ballesteros and Weinstein numbering.²¹ Transmembrane helices are labeled in red Roman numerals.

The portion of **7a-l** bearing the carboxylic acid functionality is similar to the 3-[4-(benzyloxy)phenyl]propanoic acid core of TAK-875. To investigate the conformational similarities between **7c** (~~one of the most potent compounds in the series~~) and the TAK-875 co-crystallized with the receptor, both were docked onto FFA1 (Figure 5). Indeed, the hydrophobic benzene ring of the 3-phenylpropanoic acid portion of **7c** appears beneficial for agonist activity as it matches the hydrophobic environment of the active site. The position of **7c** inside the binding cavity closely resembles that of TAK-875. However, the differences in activity is likely attributable to the variation of the agonist aromatic tail. The 2-fluorobenzene tail of **7c** points straight to the lipid side, whereas ~~in TAK-875~~, the 2,6-dimethylphenyl moiety ~~of TAK-875~~ points toward the extracellular side of the lipids. ~~The two methyl substituents control the dihedral angle of the biphenyl portion of TAK-875.~~ Methyl substitutions at position 3 keeps two aromatic rings at an angle to each other. ~~As a result, TAK-875 forms additional favorable π - π stacking contacts with F142_{4.61}.~~ In contrast, the terminal ring of **7c** connected via a rigid planar amide group extends straight and forms ~~similarly to **6a** (*vide supra*),~~ hydrophobic interactions with P80_{3.26}, V81_{3.27} and V84_{3.30}. It appears that the terminal ring of **7c** is particularly prone to steric effects. Indeed, even moderately bulky substituents (such as those present in **7b**, **7d**, **7f**, **7i** and **7k**) tend to lower the agonist potency.

Commented [IT7]: They both repeat the same thing.

Table 3. The in vitro ADME profile of compounds **6a**, **6c**, **7c** and **7l**.

<u>Physicochemical properties</u>		6a	6c	7c	7l
Plasma stability (mouse) - T _{1/2} , min		>240	>240	20.4	115.7
Plasma protein binding (mouse) - % bound ^a		92.4	94.1	ND ^b	92.8
Metabolic stability (mouse liver microsomes)	T _{1/2} , min	77.5	208.9	6.9	13.2
	CL _{int} , μ L/min/mg	21.6	8.0	241.4	126.3
LogD, pH 7.4 ^a		1.28	0.96	0.95	1.46

^a Each value is an average of n = 2, measured at c = 1 μ M.

^b Data were inconclusive due to compound's low plasma stability.

Since we were able to reach low micromolar to sub-micromolar potency in both compound series (**6** and **7**), we were also keen ~~on in~~ assessing the preliminary ADME profile, ~~(particularly with respect to plasma and liver microsomal stability)~~ for the most active compounds ~~from these series~~. As it is evident from Table 3, all compounds demonstrated ~~very~~ favorable octanol-water distribution properties (LogD measured at pH 7.4) which ~~were~~ are well within the limits of established for developable drug candidates.²² However, the metabolic and plasma stability of the two series differed significantly: compounds **6a** and **6c** displayed excellent stability (in line with our previous findings¹⁴) while compounds **7c** and **7l** were markedly unstable. This even hindered the determination of plasma protein binding for **7c**, while the other three compounds displayed a good free fraction in plasma. The latter

unfortunate aspect (which could be related to the presence of metabolically prone 4-phenoxy-[1,2,4,1,3,4](#)-thiadiazole linkage in **7a-1**) will undoubtedly affect the prospects of developing compounds belonging to series **7** as pharmacological tools or drug candidates.

Table 4. [The](#) hERG [K+ channel](#) binding profile (% $\pm$ SE)^a of compounds **6a**, **6c**, **7c** and **7l**.

	6a	6c	7c	7l
20 μ M	<u>22.0</u> $\pm$ 3.6	-1.0 $\pm$ 5.7	4.0 $\pm$ 3.3	<u>36.0</u> $\pm$ 6.8
5 μ M	2.0 $\pm$ 3.9	-1.0 $\pm$ 5.4	-7.0 $\pm$ 3.8	-3.0 $\pm$ 3.7
1 μ M	8.0 $\pm$ 4.5	-6.0 $\pm$ 3.3	9.0 $\pm$ 9.5	1.0 $\pm$ 8.9

^a Each value is an average of n = 4.

The four lead compounds (**6a**, **6c**, **7c**, **7l**) displayed ~~very~~ favorable hERG binding profile as determined using Predictor™ hERG Fluorescence Polarization Assay (see Experimental section). The modest binding of two compounds (**6a** and **7l**) can be viewed as not significant in light of the much higher potency of the compounds.

Table 5. [The](#) CYP450 inhibition profile (% inhibition $\pm$ SE)^a of compounds **6a**, **6c**, **7c** and **7l**.

CYP450	6a	6c	7c	7l
1A2	94.3 $\pm$ 0.5	47.2 $\pm$ 9.8	18.8 $\pm$ 4.5	41.9 $\pm$ 9.2
2C9	9.8 $\pm$ 9.9	-1.9 $\pm$ 5.8	12.8 $\pm$ 9.7	85.0 $\pm$ 4.9
2C19	37.2 $\pm$ 5.9	25.2 $\pm$ 5.4	-3.3 $\pm$ 3.6	77.7 $\pm$ 1.3
2D6	1.8 $\pm$ 9.2	11.8 $\pm$ 9.4	6.6 $\pm$ 14.5	22.7 $\pm$ 1.3
3A4	12.3 $\pm$ 6.3	-5.1 $\pm$ 11.1	-28.7 $\pm$ 9.6	55.2 $\pm$ 2.9

^a Each value is an average of n = 4, measured at ~~e=~~[concentration](#) 20 μ M.

The cytochrome P450 inhibition profile assessed for five principal isoforms (1A2, 2C9, 2C19, 2D6 and 3A4)²³ demonstrated that the occasional isoform-selective inhibition is not scaffold-related. Clearly, among two compounds in each series, compounds **6c** and **7c** have a markedly ‘cleaner’ profile and, hence, lower likelihood of causing drug-drug interactions due to CYP inhibition.²⁴

3. Conclusions

We have explored two chemical series as FFA1 receptor agonists: one (**6**) in which [1,2,4,1,3,4](#)-thiadiazole-2-carboxamide plays the role of the core scaffold and the other (**7**) containing a [1,2,4,1,3,4](#)-thiadiazole-2-carboxamide moiety as a periphery group ‘decorating’ the 3-phenylpropanoic acid core (the latter is common for many known advanced FFA1 agonists). Both chemical series delivered

compounds of sub-micromolar potency and excellent selectivity against a panel of other free fatty acid receptors (FFA2/GPR43, FFA3/GPR41 and FFA4/GPR120), confirming the correctness of the initial design idea. The observed SAR trends have also been rationalized by in silico docking of the most active compounds ~~onto~~in FFA1, in comparison with the earlier described ~~1,2,4~~1,3,4-thiadiazole-2-carboxamide **5** and Takeda's discontinued clinical candidate TAK-875. The best compounds in each series have been profiled for ADME parameters (plasma and metabolic stability, plasma protein binding, LogD (pH 7.4), CYP inhibition and hERG binding. Unfortunately, the low plasma and metabolic stability observed for the series 7 compounds tarnishes the series from ~~developability perspective~~future development. ~~On the contrary~~In contrast, series **6** displayed excellent plasma and metabolic stability, reasonable free fraction in plasma and a good CYP inhibition and hERG binding profile. Compound **6c** clearly standing out in terms of the overall potency and ADME profile.

Commented [IT8]: What was the idea? Not clear

4. Experimental section

4.1. General experimental

All reactions were conducted in oven-dried glassware. Melting points were measured with a Buchi B-520 melting point apparatus and were not corrected. Analytical thin-layer chromatography was carried out on Silufol UV-254 silica gel plates using appropriate mixtures of ethyl acetate and hexane. Compounds were visualized with short-wavelength UV light. ¹H NMR and ¹³C NMR spectra were recorded on Bruker MSL-300 spectrometers in DMSO-D₆-d₆ using TMS as an internal standard. Mass spectra were recorded using Shimadzu LCMS-2020 system with electron impact (EI) ionization. All and reagents and solvents were obtained from commercial sources and used without purification.

All mass-spectroscopic measurements required for determination of ADME properties were performed using Shimadzu VP HPLC system including vacuum degasser, gradient pumps, reverse phase HPLC column, column oven and autosampler. The HPLC system was coupled with tandem mass spectrometer API 3000 (PE Sciex). The TurboIonSpray ion source was used in both positive and negative ion modes. Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex).

4.2. Synthetic organic chemistry

4.2.1. Starting materials

2-Chloroacetamides **8** and **11** as well as *tert*-butyl 3-(4-hydroxyphenyl)propionate (**14**) are known and commercially available compounds.

4.2.1.1. [4-(3-*Tert*-butoxy-3-oxopropyl)phenoxy]acetic acid (13). A 250 mL round-bottomed flask was charged with a solution of *tert*-butyl 3-(4-hydroxyphenyl)propionate (**14**, 7.15 g, 32.0 mmol) in anhydrous DMF (50 mL). Freshly calcinated K₂CO₃ (3.5 g, 25.0 mmol) was added in small portions followed by a dropwise addition of a solution of ethyl bromoacetate (7.0 g, 41 mmol) in DMF (20 mL). The reaction mixture was heated, on vigorous stirring, at 60 °C for 10 h. The solvent was removed *in vacuo* and the residue was poured into water. The aqueous phase was extracted with ethyl acetate (3 x 100 mL). The combined organic extracts were washed with 5% aqueous HCl, 5% aqueous K₂CO₃ and brine, dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was dissolved in methanol (100 mL) and a solution of KOH (2.34 g) in water (10 mL) was added dropwise. The reaction mixture was stirred for 12 h at r. t. and the volatiles were removed *in vacuo*. The residue was dissolved in water (100 mL) and the solution was extracted with ethyl acetate (3 x 50 mL) and the organic extracts were discarded. The aqueous phase was carefully acidified to pH 5 with 5% aqueous HCl and extracted again with ethyl acetate (3 x 50 mL). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel using 0 → 5% gradient of methanol in chloroform as eluent to provide the title compound as a white crystalline solid (6.2 g, 22.3 mmol, 70%). M. p. 73-78 °C; ¹H NMR (300 MHz, CDCl₃) δ 10.61 (s, 1H), 7.14 (d, *J* = 8.6 Hz, 1H), 6.85 (d, *J* = 8.6 Hz, 2H), 4.66 (s, 1H), 2.86 (t, *J* = 7.7 Hz, 1H), 2.52 (t, *J* = 7.7 Hz, 1H), 1.42 (s, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 174.11, 172.65, 155.89, 134.30, 129.51, 114.59, 80.63, 64.94, 37.25, 30.25, 28.06; MS *m/z* 281.4 (M+H⁺).

4.2.2. General procedure for the preparation of compounds 6a-e

To a suspension of elementary sulfur (512 mg, 16.0 mmol) in dry DMF (20 mL) was sequentially added (in dropwise fashion) triethylamine (2.25 mL, 16.0 mmol) and morpholine (1.06 mmol) and the resulting mixture was stirred for 30 min. Then it was treated with a solution of respective 2-chloroacetamides **8** (0.5 mmol). The mixture was stirred overnight, poured into water (50 mL) and the resulting precipitate was separated by filtration and air-dried. It was then suspended in acetone (50 mL) and the insoluble residue of excess of unreacted sulfur was filtered off and discarded. The filtrate was evaporated to dryness and the dry residue was dissolved in dry DMF (15 mL), treated with hydrazine hydrate (2.5 mL) and stirred for 12 hours. The reaction mixture was poured into water, the pH of the aqueous medium was adjusted to 5.0 with 2M aqueous HCl. The resulting precipitate of **10** was filtered off and used in the next step without further purification (purity of at least 90% was estimated based on ¹H NMR analysis). Thiohydrazide **10** thus obtained was placed in a thick-walled crew-capped glass tube along with succinic anhydride (1.2 mmol) and glacial acetic acid (3.0 mL). The reaction mixture was heated at reflux temperature on vigorous stirring over 2 hours, cooled down and poured into water (25 mL).

The precipitate formed was filtered off and air dried to deliver analytically pure compounds **6a-e** in yields indicated.

4.2.2.1. 3-{5-[(3'-methylbiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6a).

Compound **6a** was obtained as a white solid (150 mg, 82%). M. p. 156-159 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.41 (s, 1H), 11.17 (s, 1H), 8.17 (s, 1H), 7.84 (dd, *J* = 7.2, 3.7 Hz, 1H), 7.49 – 7.41 (m, 4H), 7.37 (t, *J* = 7.5 Hz, 1H), 7.20 (d, *J* = 7.3 Hz, 1H), 3.40 (t, *J* = 6.9 Hz, 2H), 2.84 (t, *J* = 7.0 Hz, 2H), 2.39 (s, 3H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.64, 172.86, 165.77, 156.35, 140.78, 139.80, 138.21, 138.07, 129.24, 128.82, 128.24, 127.23, 123.71, 122.87, 119.61, 119.09, 32.71, 25.25, 21.06. HRMS (ESI) *m/z* calcd for C₁₉H₁₇N₃O₃SNa [M+Na⁺] 390.0883, found 390.0883.

4.2.2.2. 3-{5-[(3'-chlorobiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6b).

Compound **6b** was obtained as a white solid (155 mg, 80%). M. p. 159-162 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.42 (s, 1H), 11.18 (s, 1H), 8.19 (s, 1H), 7.91 (d, *J* = 6.0 Hz, 1H), 7.69 (s, 1H), 7.63 (d, *J* = 7.5 Hz, 1H), 7.56 – 7.42 (m, 5H), 3.40 (t, *J* = 6.9 Hz, 2H), 2.84 (t, *J* = 7.0 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.79, 172.99, 165.79, 156.43, 141.98, 139.08, 138.40, 133.81, 130.88, 129.54, 127.53, 126.37, 125.33, 123.03, 120.30, 119.19, 32.74, 25.31. HRMS (ESI) *m/z* calcd for C₁₈H₁₄ClN₃O₃SNa [M+Na⁺] ,410.0336, found 410.0337.

4.2.2.3. 3-{5-[(4'-fluorobiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6c).

Compound **6c** was obtained as a white solid (145 mg, 78%). M. p. 279-181 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.79 (s, 1H), 8.76 (s, 1H), 8.46 (dd, *J* = 6.5, 2.2 Hz, 1H), 8.30 (dd, *J* = 8.7, 5.5 Hz, 2H), 8.11 – 8.03 (m, 2H), 7.93 (t, *J* = 8.8 Hz, 2H), 4.01 (t, *J* = 6.9 Hz, 2H), 3.45 (t, *J* = 6.9 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.78, 173.00, 165.82, 161.99 (d, *J* = 244.63 Hz), 156.43, 139.69, 138.32, 136.36 (d, *J* = 2.94 Hz), 129.43, 128.64 (d, *J* = 8.31 Hz), 122.93, 119.73, 119.07, 115.84 (d, *J* = 21.45 Hz), 32.76, 25.31. HRMS (ESI) *m/z* calcd for C₁₈H₁₄FN₃O₃SNa 394.0632, found 394.0632.

4.2.2.4. 3-(5-{[3-(furan-2-yl)phenyl]carbamoyl}-1,3,4-thiadiazol-2-yl)propanoic acid (6d).

Compound **6d** was obtained as a white solid (110 mg, 64%). M. p. 218-221 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.42 (s, 1H), 11.18 (s, 1H), 8.25 (s, 1H), 7.75 (dd, *J* = 12.8, 4.7 Hz, 2H), 7.51 (d, *J* = 7.8 Hz, 1H), 7.42 (t, *J* = 7.9 Hz, 1H), 6.91 (d, *J* = 3.3 Hz, 1H), 6.61 (dd, *J* = 3.3, 1.8 Hz, 1H), 3.39 (t, *J* = 7.0 Hz, 2H), 2.83 (t, *J* = 6.9 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.74, 172.98, 165.77, 156.46, 152.69, 143.13, 138.30, 130.79, 129.38, 119.86, 119.81, 115.63, 112.14, 106.17, 32.72, 25.29. HRMS (ESI) *m/z* calcd for C₁₆H₁₃N₃O₄SNa [M+Na⁺] 366.0519, found 366.0519.

4.2.2.5. 3-(5-[[4-(benzyloxy)phenyl]carbamoyl]-1,3,4-thiadiazol-2-yl)propanoic acid (6e).

Compound **6e** was obtained as a white solid (146 mg, 76%). M. p. 205-207 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.42 (s, 1H), 11.00 (s, 1H), 7.74 (d, *J* = 8.6 Hz, 2H), 7.3 – 7.5 (m, 5H), 7.02 (d, *J* = 8.6 Hz, 2H), 5.10 (s, 2H), 3.38 (t, *J* = 6.7 Hz, 2H), 2.82 (t, *J* = 6.7 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.89, 173.36, 166.45, 156.34, 155.74, 137.55, 131.41, 128.88, 128.27, 128.14, 122.76, 115.33, 69.86, 33.24, 25.73. HRMS (ESI) *m/z* calcd for C₁₉H₁₇N₃O₄SNa [M+Na⁺] 406.0835, found 406.0837.

4.2.3. General procedure for the preparation of compounds 7a-l

Compounds **7a-l** were prepared in the same manner and on the same scale (0.5 mmol of 2-chloroacetanilides **11**) as described above for the preparation of compounds **6a-e**, except for the [4,2,41.3,4](#)-thiadiazole-forming step. To a solution of [4-(3-*tert*-butoxy-3-oxopropyl)phenoxy]acetic acid (**13**, 0.5 mmol, 140 mg) in DCM (4 mL) carbonyldiimidazole (0.55 mmol, 90 mg) was added and the mixture was stirred at r. t. for 30 min. To the resulting solution of the carboxylic acid imidazolidine, thiohydrazide **12** (obtained in the reaction of 2-chloroacetanilide **11** with morpholine and elementary sulfur in the presence of Et₃N followed by treatment with hydrazine hydrate) was added and the reaction mixture was stirred at r. t. for 16 h. The solvent was removed *in vacuo*, the residue was dissolved in glacial acetic acid (3 mL) and the solution was heated at reflux for 30 min. It was then cooled down to r. t., poured into water (50 mL) and the resulting precipitate was collected by filtration and dried *in vacuo*. It was then combined with 4M solution of HCl in 1,4-dioxane (5 mL); the mixture was stirred at r. t. for 16 h and poured into water (50 mL). The precipitate was collected by filtration, washed with water and air-dried to provide compound **7a-l** in yields indicated.

4.2.3.1. 3-(4-([5-(Phenylcarbamoyl)-1,3,4-thiadiazol-2-yl]methoxy}phenyl)propanoic acid (7a).

Compound **7a** was obtained as a white solid (115 mg, 60%). M. p. 199-206 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.13 (s, 1H), 11.20 (s, 1H), 7.84 (d, *J* = 7.9 Hz, 2H), 7.38 (t, *J* = 7.8 Hz, 2H), 7.17 (dd, *J* = 11.5, 8.0 Hz, 3H), 7.01 (d, *J* = 8.5 Hz, 2H), 5.64 (s, 2H), 2.77 (t, *J* = 7.5 Hz, 2H), 2.50 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.79, 171.65, 166.76, 156.03, 155.47, 137.66, 134.32, 129.45, 128.79, 124.77, 120.83, 114.93, 64.31, 35.43, 29.49. HRMS (ESI) *m/z* calcd for C₁₉H₁₇N₃O₄SNa [M+Na⁺], 406.0832, found 406.0832.

4.2.3.2. 3-[4-([5-(4-Methoxyphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl]methoxy}phenyl]propanoic acid (7b).

Compound **7b** was obtained as a white solid (128 mg, 62%). M. p. 198-203 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.12 (s, 1H), 11.09 (s, 1H), 7.76 (d, *J* = 7.9 Hz, 2H), 7.19 (d, *J* = 7.4 Hz, 2H), 6.98 (dd, *J* = 19.8, 7.9 Hz, 4H), 5.63 (s, 2H), 3.74 (s, 3H), 2.77 (t, *J* = 7.5 Hz, 2H), 2.50 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.81, 171.45, 166.95, 156.25, 155.57, 155.48, 134.32, 130.68,

129.45 122.33, 114.93, 113.90, 64.31, 55.21, 35.44, 29.50. HRMS (ESI) m/z calcd for $C_{20}H_{19}N_3O_5SNa$ $[M+Na^+]$ 436.0937, found 436.0938.

4.2.3.3. 3-[4-((5-[(2-Fluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl)methoxy)phenyl]propanoic acid (7c). Compound **7c** was obtained as a white solid (116 mg, 58%). M. p. 198-201 °C; 1H NMR (300 MHz, DMSO- d_6) δ 12.12 (s, 1H), 10.94 (s, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.33 (dd, J = 8.3, 3.7 Hz, 2H), 7.25 (dd, J = 7.4, 4.2 Hz, 1H), 7.19 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 8.5 Hz, 2H), 5.66 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 2H); ^{13}C NMR (75 MHz, DMSO- d_6) δ 173.65, 171.71, 165.70, 156.17, 155.69 (d, J = 248.09 Hz), 155.40, 134.30, 129.36, 127.80 (d, J = 8.31 Hz), 126.95 (d, J = 1.21 Hz), 124.43 (d, J = 3.63 Hz), 124.08 (d, J = 12.28 Hz), 115.93 (d, J = 19.55 Hz), 114.91, 64.26, 35.35, 29.43. HRMS (ESI) m/z calcd for $C_{19}H_{16}FN_3O_4SNa$ $[M+Na^+]$ 424.0737, found 424.0738.

4.2.3.4. 3-[4-((5-[(3-Methylphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl)methoxy)phenyl]propanoic acid (7d). Compound **7d** was obtained as a white solid (107 mg, 54%). M. p. 185-189 °C; 1H NMR (300 MHz, DMSO- d_6) δ 11.10 (s, 1H), 7.69 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 7.25 (t, J = 7.8 Hz, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.00 (t, J = 8.0 Hz, 3H), 5.64 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 2H), 2.31 (s, 3H); ^{13}C NMR (75 MHz, DMSO- d_6) δ 173.65, 171.48, 166.69, 155.90, 155.43, 137.92, 137.48, 134.28, 129.35, 128.51, 125.39, 121.27, 117.99, 114.89, 64.28, 35.35, 29.43, 21.12. HRMS (ESI) m/z calcd for $C_{20}H_{19}N_3O_4SNa$ $[M+Na^+]$ 420.0988, found 420.0988.

4.2.3.5. 3-[4-((5-[(4-Fluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl)methoxy)phenyl]propanoic acid (7e). Compound **7e** was obtained as a white solid (116 mg, 58%). M. p. 192-197 °C; 1H NMR (300 MHz, DMSO- d_6) δ 12.12 (s, 1H), 11.28 (s, 1H), 7.87 (dd, J = 9.0, 5.0 Hz, 2H), 7.29 – 7.14 (m, 4H), 7.01 (d, J = 8.5 Hz, 2H), 5.64 (s, 2H), 3.56 (s, 3H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.4 Hz, 2H); ^{13}C NMR (75 MHz, DMSO- d_6) δ 173.65, 171.57, 166.54, 158.84 (d, J = 241.69 Hz), 155.92, 155.42, 134.29, 133.96 (d, J = 2.59 Hz), 129.35, 122.72 (d, J = 8.13 Hz), 115.36 (d, J = 22.49 Hz), 114.90, 64.28, 35.35, 29.43. HRMS (ESI) m/z calcd for $C_{19}H_{16}FN_3O_4SNa$ $[M+Na^+]$ 424.0737, found 424.0738.

4.2.3.6. 3-[4-((5-[(2-methylphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl)methoxy)phenyl]propanoic acid (7f). Compound **7f** was obtained as a white solid (111 mg, 56%). M. p. 188-192 °C; 1H NMR (300 MHz, DMSO- d_6) δ 12.12 (s, 1H), 10.71 (s, 1H), 7.42 – 7.36 (m, 1H), 7.31 – 7.25 (m, 1H), 7.25 – 7.21 (m, 2H), 7.19 (d, J = 8.5 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 5.65 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 2H), 2.25 (s, 3H); ^{13}C NMR (75 MHz, DMSO- d_6) δ 173.78, 171.57, 166.45, 156.15, 155.45, 134.85, 134.31, 133.59, 130.46, 129.45, 126.69, 126.36, 126.16, 114.92, 64.24, 35.42, 29.48, 17.76. HRMS (ESI) m/z calcd for $C_{20}H_{19}N_3O_4SNa$ $[M+Na^+]$ 420.0988, found 420.0988.

4.2.3.7. 3-[4-({5-[(4-chlorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid (7g). Compound **7g** was obtained as a white solid (131 mg, 63%). M. p. 220-222°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.12 (s, 1H), 11.35 (s, 1H), 7.88 (d, *J* = 8.9 Hz, 2H), 7.44 (d, *J* = 8.8 Hz, 2H), 7.19 (d, *J* = 8.5 Hz, 2H), 7.01 (d, *J* = 8.6 Hz, 2H), 5.64 (s, 2H), 2.77 (t, *J* = 7.5 Hz, 2H), 2.50 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.78, 171.77, 165.60, 156.14, 155.45, 136.67, 134.33, 129.44, 128.72, 128.48, 122.36, 114.92, 64.31, 35.44, 29.49. HRMS (ESI) *m/z* calcd for C₁₉H₁₆ClN₃O₄Na [M+Na⁺] 440.0442, found 440.0442.

4.2.3.8. 3-[4-({5-[(3-fluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid (7h). Compound **7h** was obtained as a white solid (110 mg, 55%). M. p. 177-181°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.12 (s, 1H), 11.40 (s, 1H), 7.81 – 7.66 (m, 2H), 7.41 (dd, *J* = 15.2, 8.1 Hz, 1H), 7.19 (d, *J* = 8.6 Hz, 2H), 7.07 – 6.94 (m, 3H), 5.65 (s, 2H), 2.77 (t, *J* = 7.5 Hz, 2H), 2.50 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.67, 171.77, 166.33, 161.92 (d, *J* = 241.69 Hz), 156.24, 155.43, 139.33 (d, *J* = 10.90 Hz), 134.31, 130.38 (d, *J* = 9.34 Hz), 129.36, 116.55 (d, *J* = 2.77 Hz), 114.91, 111.22 (d, *J* = 21.10 Hz), 107.56 (d, *J* = 26.29 Hz), 64.31, 35.36, 29.45. HRMS (ESI) *m/z* calcd for C₁₉H₁₆FN₃O₄Na [M+Na⁺] 424.0737, found 424.0738.

4.2.3.9. 3-[4-({5-[(3-methoxyphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid (7i). Compound **7i** was obtained as a white solid (128 mg, 62%). M. p. 156-160°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.14 (s, 1H), 11.15 (s, 1H), 7.52 (s, 1H), 7.46 (d, *J* = 7.9 Hz, 1H), 7.27 (t, *J* = 8.1 Hz, 1H), 7.19 (d, *J* = 8.3 Hz, 1H), 7.01 (d, *J* = 8.3 Hz, 2H), 6.75 (d, *J* = 7.9 Hz, 1H), 5.64 (s, 2H), 3.75 (s, 3H), 2.77 (t, *J* = 7.3 Hz, 2H), 2.50 (t, *J* = 7.2 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.67, 171.57, 166.65, 159.40, 155.97, 155.44, 138.75, 134.30, 129.51, 129.36, 114.91, 112.94, 110.19, 106.59, 64.30, 55.02, 35.37, 29.45. HRMS (ESI) *m/z* calcd for C₂₀H₁₉N₃O₅Na [M+Na⁺] 436.0937, found 436.0938.

4.2.3.10. 3-[4-({5-[(3,4-difluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid (7j). Compound **7j** was obtained as a white solid (147 mg, 70%). M. p. 208-213°C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.12 (s, 1H), 11.44 (s, 1H), 7.95 (ddd, *J* = 12.9, 7.4, 2.3 Hz, 1H), 7.73 – 7.62 (m, 1H), 7.46 (dd, *J* = 19.6, 9.3 Hz, 1H), 7.19 (d, *J* = 8.5 Hz, 2H), 7.01 (d, *J* = 8.5 Hz, 2H), 5.64 (s, 2H), 2.77 (t, *J* = 7.5 Hz, 2H), 2.49 (t, *J* = 7.3 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.66, 171.79, 166.21, 156.17, 155.42, 148.78 (dd, *J* = 13.32 Hz, 243.59 Hz), 146.15 (dd, *J* = 12.63 Hz, 243.59 Hz), 134.62 (dd, *J* = 2.94 Hz, 9.17 Hz), 134.31, 129.35, 117.45 (d, *J* = 17.48 Hz), 117.28 (dd, *J* = 3.63 Hz, 5.36 Hz), 114.90, 109.88 (d, *J* = 21.80 Hz), 64.29, 35.36, 29.43. HRMS (ESI) *m/z* calcd for C₁₉H₁₅F₂N₃O₄Na [M+Na⁺] 442.0643, found 442.0644.

4.2.3.11. 3-[4-({5-[(4-methylphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid (7k). Compound **7k** was obtained as a white solid (107 mg, 54%). M. p. 185-189 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.11 (s, 1H), 11.12 (s, 1H), 7.72 (d, *J* = 8.4 Hz, 2H), 7.18 (dd, *J* = 8.3, 3.6 Hz, 4H), 7.01 (d, *J* = 8.5 Hz, 2H), 5.64 (s, 2H), 2.77 (t, *J* = 7.5 Hz, 2H), 2.50 (t, *J* = 7.5 Hz, 3H), 2.26 (d, *J* = 12.0 Hz, 3H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.79, 171.54, 166.86, 155.81, 155.47, 135.15, 134.31, 133.87, 129.44, 129.17, 120.75, 114.93, 64.30, 35.43, 29.49, 20.55. HRMS (ESI) *m/z* calcd for C₂₀H₁₉N₃O₄SNa [M+Na⁺] 420.0988, found 420.0988.

4.2.3.12. 3-[4-({5-[(3-chlorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid (7l). Compound **7l** was obtained as a white solid (113 mg, 54%). M. p. 171-173 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.10 (s, 1H), 11.39 (s, 1H), 8.00 (s, 1H), 7.81 (d, *J* = 8.2 Hz, 1H), 7.41 (t, *J* = 8.1 Hz, 1H), 7.25 – 7.15 (m, 3H), 7.01 (d, *J* = 8.6 Hz, 2H), 5.65 (s, 2H), 2.77 (t, *J* = 7.5 Hz, 2H), 2.50 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.78, 171.88, 166.38, 156.33, 155.45, 139.15, 134.33, 133.04, 130.50, 129.44, 124.49, 120.27, 119.24, 114.92, 64.30, 35.43, 29.48. HRMS (ESI) *m/z* calcd for C₁₉H₁₆ClN₃O₄SNa [M+Na⁺] 440.0442, found 440.0442.

4.3 Molecular modeling

4.3.1. Protein structure source and preparation for docking

The crystal structure of FFA1 complexed with TAK-875, with PDB code: 4phu was used for docking studies.²⁵ All *in silico* work pertaining to docking and protein preparation was carried out using the specified modules within Schrodinger's maestro, version 2016-1.²⁶ To prepare FFA1 for docking, hydrogens, missing atoms and alternate residue positions were defined followed by optimization of the hydrogen bonding network by re-orienting hydroxyl and amide groups of Asn and Gln and identifying an appropriate orientation of the imidazole ring of His residues using Protein Preparation Wizard.²⁷

4.3.2. Docking protocol.

The mutant A188 made for thermal stability during crystallization was mutated back to Phe followed by extensive sampling for the side-chain position. Careful positioning of the phenyl group was needed as Phe88 can be considered as an import residue in stabilizing protein-ligand binding and may influence docking results substantially. The conformation was sampled using MacroModel's Conformational Search.²⁸ To alleviate any protein strain occurring from this point mutation, while reducing deviation from the original crystal structure coordinates, a tightly controlled, two stage minimization protocol was applied, i.e. hydrogen only minimization followed by a minimization based on constraints set from the

Commented [DM9]: I don't believe it makes sense to have separate subtitle for docking protocol, as protein preparation is contained in both.

X-ray derived B factors. ~~Minimisation~~Minimization was performed using MacroModel.²⁸ In deciding on a final position of Phe88 and ensuring a correct docking protocol was used, TAK-875 was re-docked onto the receptor and compared to the position obtained in the crystal structure, ~~an~~-RMSD of ≤ 2.5 Å. Prior to docking, agonists were created manually in maestro, the 2D structures were then optimized to produce a low-energy 3D structure using LigPrep.²⁹ Glide³⁰ was used for receptor grid generation and ligand docking. The centroid of the receptor grid was defined by using TAK-875's crystal structure conformation. Ligands were docked using the extra precision (XP) algorithm while enhancing the planarity of conjugated pi groups. The OPLS3, all-atom force-field was employed for all calculations. In labelling the protein residues of FFA1 in figure 4 and figure 5 the number in subscript represents the Ballesteros Weinstein indexing system.²¹

4.4 Biological and ADME assays

4.4.1. Determination of agonistic activity of compounds against GPR40, GPR41, GPR43 and GPR120 receptors

CHO cells stably expressing GPCRs (CHO-GPR40 purchased from The European Collection of Cell Cultures, ECACC) were seeded (12500cells/well) into 384-well black-wall, clear-bottom microtiter plates 24 h prior to assay. Cells were loaded for 1 h with calcium assay kit and tested using fluorometric imaging plate reader (FLIPR Tetra High Throughput Cellular Screening System by Molecular Devices). Maximum change in fluorescence over base line was used to determine agonist response. A potent and selective agonist for FFA1 (GPR40) GW9508 (Selleckchem, S8014) was tested with the test compounds as a positive control. Concentration response curve data were fitted using Molecular Devices ScreenWorks® System Control Software (Molecular Devices).

For specificity screening for possible GPR41, 43 and 120 agonism, CHO cell lines stably expressing the respective receptors (also purchased from The European Collection of Cell Cultures, ECACC) were used.

4.4.2. Determination of the distribution coefficient (LogD, pH 7.4)

The partitioning ratio of compounds **6a**, **6c**, **7c** and **7l** and one reference compound ($\log D_{\text{pH}7} = 2.93$) was determined in *n*-octanol – phosphate buffer saline (PBS) using shake-flask method which consists of equilibrating a certain amount of a solute within the biphasic system and determining the concentration in each phase using LC-MS/MS. Equilibration was carried out in Eppendorf-type polypropylene microtubes in duplicates. 5 µL aliquots of 10 mM DMSO stock solution were added to a manually pre-equilibrated mixture of PBS (500 µL) and *n*-octanol (500 µL) and the resulting mixture was shaken for 1h at 30 rpm. Phase separation was achieved by centrifugation for 2 min at 6000 rpm. The *n*-octanol

phase was diluted 100-fold with 40% aqueous acetonitrile and the PBS phase was diluted 10-fold with 5% aqueous acetonitrile. The partitioning ratio (D) was calculated using the formula:

$$D = \frac{100 \cdot S_o}{1 \cdot S_p},$$

where S_o – peak area of the analyte in the *n*-octanol phase, S_p – peak area of the analyte in PBS phase.

4.4.3. Assessment of metabolic stability in mouse liver microsomes

The metabolic stability of compound **6a**, **6c**, **7c** and **7l** as well as the reference compound (~~Propranolol~~) ~~was measured~~ in liver microsomes at five time points over 40 minutes using HPLC-MS. Metabolic stability is defined as the percentage ~~loss~~ of parent compound ~~-test~~ over time in the presence of a metabolically active test system, such as rodent liver microsomal fractions.

Mouse hepatic microsomes were isolated from pooled (50), perfused livers of BALB/c male mice according to the standard protocol.³¹ The batch of microsomes was tested for quality control using a commercial comparator preparation (Sigma-Aldrich M9441) and verapamil as reference compound. Microsomal incubations were carried out in 96-well plates in 5 aliquots of 40 µL each (one for each time point). Liver microsomal incubation medium contained potassium phosphate buffer (100 mM, pH 7.4), MgCl₂ (3.3 mM), NADPH (3 mM), glucose-6-phosphate (5.3 mM), glucose-6-phosphate dehydrogenase (0.67 units/ml) with 0.42 mg of liver microsomal protein per ml. In addition, control incubations were performed replacing the NADPH-regenerating system with 100 mM phosphate buffer pH 7.4. Test compounds (2 µM, final solvent concentration 1.6 %) were incubated at 37°C under vortexing at 100 rpm. Five time points over 40 minutes had been analyzed. The reactions were stopped by adding 12 volumes of 90% acetonitrile-water to 40 µL incubation aliquots, followed by plasma protein precipitation by centrifuging at 5500 rpm for 3 minutes. Incubations were performed in duplicates. Supernatants were analyzed using the HPLC system coupled with tandem mass spectrometer. The elimination constant (k_{el}), half-life ($T_{1/2}$) and intrinsic clearance (CL_{int}) were determined in plot of $\ln(AUC)$ versus time, using linear regression analysis:

$$k_{el} = - \text{slope}$$

$$T_{1/2} = 0.693/k_{el}$$

$$CL_{int} = (0.693/ T_{1/2}) \times (\mu\text{l incubation/mg microsomes})$$

4.4.4. Analysis of mouse plasma protein binding

The binding of compound **6a**, **6c**, **7c** and **7l** as well as the reference compound (Verapamil) to mouse plasma proteins was evaluated using HPLC-MS/MS. The task was performed by spiking test compounds

at concentration of 1 μM into mice plasma (Lampire Biological Labs, US, catalog number 7304309) and dialyzing against buffer until equilibrium is achieved. Concentrations of the compounds in both plasma and buffer were determined to calculate the percentage of plasma protein bound compounds.

The assay was performed in the 96-well equilibrium dialysis apparatus (HTDialysis, LLC). Each individual well unit consisted of 2 chambers separated by a vertically aligned dialysis membrane of predetermined pore size (MWCO 12-14 kDa). 120 μL of plasma spiked with the compound (1 μM , final solvent concentration 1%) was added to one chamber and the same aliquot of PBS buffer, pH 7.4 was added to the other chamber. After that, HTD96b dialyzer was covered with adhesive sealing film and incubated at 37°C on an orbital shaker at 100 rpm for 5 hours. An aliquot of the content of each chamber had been taken and mixed with the same volume aliquot of the blank opposite matrix. In order to define non-specific loss of the compound during this assay, standard solution was created by mixing an aliquot of spiked plasma, which was incubated at 37°C without dialysis, with blank buffer. Sample of 1 μM series was diluted with 100% acetonitrile 10-fold with subsequent plasma proteins precipitation by centrifuging at 6000 rpm for 5 minutes. Incubations were performed in quadruplicates. Supernatants were analyzed using HPLC system coupled with tandem mass spectrometer. The unbound compound fraction is calculated as the peak ratio of the analyte in the buffer compartment divided by the same parameter in the corresponding plasma compartment.

The following equation was used to determine the extent of plasma protein binding:

$$\text{protein_binding} = \left(1 - \frac{\text{peak_area_in_dialysate_buffer}}{\text{peak_area_in_dialysate_plasma}} \right) \cdot 100\%$$

$$\text{Recovery} = \left(\frac{\text{peak_area_in_dialysate_buffer} + \text{peak_area_in_dialysate_plasma}}{\text{peak_area_in_standard_solution}} \right) \cdot 100\%$$

4.4.5. Analysis of stability in mouse plasma

Five 40 μL aliquots of 1 μM solution (final DMSO concentration 1%) of each of the compounds (**6a**, **6c**, **7c**, **7l** and two reference compounds – verapamil and propantheline) were incubated with mouse plasma (Lampire Biological Labs, US, catalog number 7304309) at 37 °C with shaking at 100 rpm. Five time points over 120 min were analyzed. The reactions were stopped by the addition of acetonitrile (200 μL) and the plasma proteins were sedimented by 5 min centrifugation at 5500 rpm. Supernatants were analyzed by LC-MS/MS. The percentage of the test compounds remaining after incubation in plasma and their half-lives ($T_{1/2}$) were determined.

4.4.6. CYP450 inhibition

The inhibition of major CYP450 isoforms (1A2, 2C9, 2C19, 2D6, 3A4) by compounds **6a**, **6c**, **7c** and **7l** at a 20 μM concentration was evaluated using P450-Glo™ Assay Systems (Promega) in accordance with the manufacturer's protocols. A conventional cytochrome P450 reaction was performed by incubating the cytochrome P450 and a luminogenic cytochrome P450 substrate. All test points were performed in quadruplicates. Control membranes (without CYPs) represent the Negative control (baseline). DMSO final concentration was 0.25%. The following reference compounds were used to assess CYP inhibition:

CYP	Reference inhibitor	Concentration , μM	% inhibition
1A2	α -Naphthoflavone	4	99.21
2C9	Fluconazole	120	89.09
2C19	Omeprazole	24	93.40
2D6	Quinidine	1	96.25
3A4	Ketoconazole	20	95.37

Concentrations of alfa-naphthoflavone, quinidine, ketoconazole, fluconazole and omeprazole are shown as 4x of Promega protocol recommendations or 4x of their IC_{50} found in the literature.³²⁻³³

4.4.7. hERG binding

Assessment of compounds' binding to hERG (human Ether-a-go-go-Related Gene) channel was performed using Predictor™ hERG Fluorescence Polarization Assay kit (Invitrogen, US, catalog number PV5365) according to manufacturer's protocol. The hERG reaction was performed by incubating the tracer (a small fluorescent molecule) and cell membranes containing hERG channel with the solutions of the test compounds (1 μM , 5 μM , 20 μM) for 4 hours. The difference of fluorescence polarization from the maximal value (no compound) was used as a measure of compound's binding to hERG channel. A strong hERG binder (compound E-4031 provided as a part of the test kit) was used as a positive control (it's reported IC_{50} value is 70 nM was confirmed experimentally prior to carrying out the testing). All measurement were performed in quadruplicates.

Acknowledgements

This research was supported by the Russian Scientific Fund (project grant 14-50-00069). We are grateful to the Center for Chemical Analysis and Materials Research of Saint-Petersburg State University for providing high-resolution mass-spectrometry data.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/xxx>.

References and notes

1. Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; Ellis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R.; Shabon, U.; Spinage, L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; Muir, A. I. *J. Biol. Chem.* **2003**, *278*, 11303–11311.
2. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. *Nature* **2003**, *422*, 173–176.
3. Watterson, K. R.; Hudson, B. D.; Ulven, T.; Milligan, G. *Front. Endocrinol.* **2014**, *5*, 137.
4. Defossa, E.; Wagner, M. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 2991–3000.
5. <https://clinicaltrials.gov>, last accessed on March 7, 2016.
6. Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R. *Diabetes Obes. Metab.* **2015**, *17*, 675–681.
7. Mancini, A. D.; Poitout, V. *Diabetes Obes. Metab.* **2015**, *17*, 622–629.
8. Lin, D. C.-H.; Zhang, J.; Zhuang, R.; Li, F.; Nguyen, K.; Chen, M.; TRan, T.; Lopez, E.; Lu, J. Y. L.; Li, X. N.; Tang, L.; Tonn, G. R.; Swaminath, G.; Reagan, J. D.; Chen, J.-L.; Tian, H.; Lin, Y.-J.; Houze, J. B.; Luo, J. *PlosOne* **2011**, *6*, e27270.
9. Zahanich, I.; Kondratov, I.; Naumchyk, V.; Kheylik, Y.; Platonov, M.; Zozulya, S.; Krasavin, M. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 3105–3111.
10. Maekawa, T.; Hara, R.; Odaka, H.; Fukatsu, K.; Mizufune, H. PCT Int. Appl. WO 2003099793A1; *Chem. Abstr.* **2003**, *140*, 951003.
11. Hamamura, K.; Sasaki, S.; Amano, Y.; Sakamoto, J.; Fukatsu, K. PCT Int. Appl. WO 2004022551A1; *Chem. Abstr.* **2004**, *140*, 220326.
12. Yasuma, T.; Negoro, N.; Sasaki, S. PCT Int. Appl. WO 2005087710 A1; *Chem. Abstr.* **2005**, *143*, 1021733.
13. Rharma, R.; Akerman, M.; Cardozo, M. G.; Houze, J.; Li, A.-R.; Liu, J.; Liu, J.; Ma, Z.; Medina, J.C.; Schmitt, M. J.; Sun, Y.; Wang, Y.; Wang, Z.; Zhu, L. PCT Int. Appl. WO 2007106469 A2; *Chem. Abstr.* **2007**, *147*, 1064386.
14. Krasavin, M.; Lukin, A.; Zhurilo, N.; Kovalenko, A.; Zahanich, I.; Zozulya, S. *J. Enzyme Inhib. Med. Chem.* **2016**, DOI: 10.3109/14756366.2016.1142984.

15. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. *ACS Med. Chem. Lett.* **2010**, *1*, 290-294.
16. Calculations were performed using ACD/Labs 6.00 software.
17. Yarovenko, V. N.; Shirokov, A. V.; Krupinova, O. N.; Zavarzin, I. V.; Krayushkin M. M. *Russ. J. Org. Chem.* **2003**, *39*, 1133-1139.
18. Ichimura, A.; Hirasawa, A.; Hara, T.; Tsujimoto, G. *Prostaglandins Other Lipid Mediat.* **2009**, *89*, 82-88.
19. Brown, J. A.; Goldsworthy, S. M.; Barnes, A. A.; Ellert, M. M.; Tcheang, L.; Daniels, D.; Muir, A. I.; Wogglesworth, M. J.; Kinghorn, I.; Fraser, N. J.; Pike, N. B.; Sturn, J. C.; Steplewski, K. M; Murdoch, P. R.; Holder, J. C.; Marshall, F. H.; Szekeres, P. G.; Wilson, S.; Ignar, D. M.; Foord, M. S.; Wise, A.; Dowell, S. J. *J. Biol. Chem.* **2003**, *278*, 11312-11319.
20. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. *Nat. Med.* **2005**, *11*, 90-94.
21. Ballesteros, J.; Weinstein, H. *Biophys. J.* **1995**, *68*, A446.
22. Ritchie, T. J.; Macdonald, S. J. F. *Drug Discov. Today* **2009**, *14*, 1011-1020.
23. Yoshimoto, K.; Echizen, H.; Chiba, K.; Tani, M.; Ishizaki, T. *Br. J. Clin. Pharmacol.* **1995**, *39*, 421-431.
24. Braenden, G.; Sjoegren, T.; Schnecke, V.; Xue, Y. *Drug Discov. Today* **2014**, *19*, 905-911.
25. Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.; Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; Aertgeerts, K.; Nguyen, J.; Jennings, A.; Okada, K. *Nature* **2014**, *513*, 124-129.
26. Schrödinger, Maestro version 10.5, LLC, New York, NY, 2016.
27. Sastry, G. M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. *J. Comput. Aid. Mol. Des.* **2013**, *27*, 221-234.
28. Schrödinger, MacroModel version 11.1, LLC, New York, NY, 2016.
29. Schrödinger, Ligprep version 3.7, LLC, New York, NY, 2016.
30. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. *J. Med. Chem.* **2004**, *47*, 1739-1749.
31. Hill, J. R. In *Current Protocols in Pharmacology* 7.8.1-7.8.11, Wiley Interscience, 2003.
32. Li, X.-Q.; Andersson, T. B.; Ahlström M.; Weidolf, L. *Drug Metab. Dispos.* **2004**, *32*, 821-827;
33. Niwa, T.; Shiraga, T.; Takagi, A. *Biol. Pharm. Bull.* **2005**, *28*, 1805-1808.